Cargando…

The Apolipoprotein A-I Mimetic L-4F Attenuates Monocyte Activation and Adverse Cardiac Remodeling after Myocardial Infarction

Excessive inflammation after myocardial infarction (MI) can promote infarct expansion and adverse left ventricular (LV) remodeling. L-4F, a mimetic peptide of apolipoprotein A-I (apoA-I), exhibits anti-inflammatory and anti-atherogenic properties; however, whether L-4F imparts beneficial effects aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamid, Tariq, Ismahil, Mohamed Ameen, Bansal, Shyam S., Patel, Bindiya, Goel, Mehak, White, C. Roger, Anantharamaiah, G. M., Prabhu, Sumanth D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279031/
https://www.ncbi.nlm.nih.gov/pubmed/32429244
http://dx.doi.org/10.3390/ijms21103519
_version_ 1783543469062488064
author Hamid, Tariq
Ismahil, Mohamed Ameen
Bansal, Shyam S.
Patel, Bindiya
Goel, Mehak
White, C. Roger
Anantharamaiah, G. M.
Prabhu, Sumanth D.
author_facet Hamid, Tariq
Ismahil, Mohamed Ameen
Bansal, Shyam S.
Patel, Bindiya
Goel, Mehak
White, C. Roger
Anantharamaiah, G. M.
Prabhu, Sumanth D.
author_sort Hamid, Tariq
collection PubMed
description Excessive inflammation after myocardial infarction (MI) can promote infarct expansion and adverse left ventricular (LV) remodeling. L-4F, a mimetic peptide of apolipoprotein A-I (apoA-I), exhibits anti-inflammatory and anti-atherogenic properties; however, whether L-4F imparts beneficial effects after myocardial infarction (MI) is unknown. Here we demonstrate that L-4F suppresses the expansion of blood, splenic, and myocardial pro-inflammatory monocytes and macrophages in a mouse model of reperfused MI. Changes in immune cell profiles were accompanied by alleviation of post-MI LV remodeling and dysfunction. In vitro, L-4F also inhibited pro-inflammatory and glycolytic gene expression in macrophages. In summary, L-4F treatment prevents prolonged and excessive inflammation after MI, in part through modulation of pro-inflammatory monocytes and macrophages, and improves post-MI LV remodeling. These data suggest that L-4F could be a used as a therapeutic adjunct in humans with MI to limit inflammation and alleviate the progression to heart failure.
format Online
Article
Text
id pubmed-7279031
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72790312020-06-15 The Apolipoprotein A-I Mimetic L-4F Attenuates Monocyte Activation and Adverse Cardiac Remodeling after Myocardial Infarction Hamid, Tariq Ismahil, Mohamed Ameen Bansal, Shyam S. Patel, Bindiya Goel, Mehak White, C. Roger Anantharamaiah, G. M. Prabhu, Sumanth D. Int J Mol Sci Article Excessive inflammation after myocardial infarction (MI) can promote infarct expansion and adverse left ventricular (LV) remodeling. L-4F, a mimetic peptide of apolipoprotein A-I (apoA-I), exhibits anti-inflammatory and anti-atherogenic properties; however, whether L-4F imparts beneficial effects after myocardial infarction (MI) is unknown. Here we demonstrate that L-4F suppresses the expansion of blood, splenic, and myocardial pro-inflammatory monocytes and macrophages in a mouse model of reperfused MI. Changes in immune cell profiles were accompanied by alleviation of post-MI LV remodeling and dysfunction. In vitro, L-4F also inhibited pro-inflammatory and glycolytic gene expression in macrophages. In summary, L-4F treatment prevents prolonged and excessive inflammation after MI, in part through modulation of pro-inflammatory monocytes and macrophages, and improves post-MI LV remodeling. These data suggest that L-4F could be a used as a therapeutic adjunct in humans with MI to limit inflammation and alleviate the progression to heart failure. MDPI 2020-05-15 /pmc/articles/PMC7279031/ /pubmed/32429244 http://dx.doi.org/10.3390/ijms21103519 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hamid, Tariq
Ismahil, Mohamed Ameen
Bansal, Shyam S.
Patel, Bindiya
Goel, Mehak
White, C. Roger
Anantharamaiah, G. M.
Prabhu, Sumanth D.
The Apolipoprotein A-I Mimetic L-4F Attenuates Monocyte Activation and Adverse Cardiac Remodeling after Myocardial Infarction
title The Apolipoprotein A-I Mimetic L-4F Attenuates Monocyte Activation and Adverse Cardiac Remodeling after Myocardial Infarction
title_full The Apolipoprotein A-I Mimetic L-4F Attenuates Monocyte Activation and Adverse Cardiac Remodeling after Myocardial Infarction
title_fullStr The Apolipoprotein A-I Mimetic L-4F Attenuates Monocyte Activation and Adverse Cardiac Remodeling after Myocardial Infarction
title_full_unstemmed The Apolipoprotein A-I Mimetic L-4F Attenuates Monocyte Activation and Adverse Cardiac Remodeling after Myocardial Infarction
title_short The Apolipoprotein A-I Mimetic L-4F Attenuates Monocyte Activation and Adverse Cardiac Remodeling after Myocardial Infarction
title_sort apolipoprotein a-i mimetic l-4f attenuates monocyte activation and adverse cardiac remodeling after myocardial infarction
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279031/
https://www.ncbi.nlm.nih.gov/pubmed/32429244
http://dx.doi.org/10.3390/ijms21103519
work_keys_str_mv AT hamidtariq theapolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction
AT ismahilmohamedameen theapolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction
AT bansalshyams theapolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction
AT patelbindiya theapolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction
AT goelmehak theapolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction
AT whitecroger theapolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction
AT anantharamaiahgm theapolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction
AT prabhusumanthd theapolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction
AT hamidtariq apolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction
AT ismahilmohamedameen apolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction
AT bansalshyams apolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction
AT patelbindiya apolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction
AT goelmehak apolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction
AT whitecroger apolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction
AT anantharamaiahgm apolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction
AT prabhusumanthd apolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction